Back to Search Start Over

ChTO DELAT', ESLI V PERIOD LEChENIYa INGIBITORAMI FAKTORA NEKROZA OPUKhOLI α VOZNIK PSORIAZ?

Authors :
Yu. V. Muravyev
I. A. Doroshkevich
Source :
Научно-практическая ревматология, Vol 49, Iss 5, Pp 89-91 (2011)
Publication Year :
2011
Publisher :
Mediar Press, 2011.

Abstract

Ingibitory faktora nekroza opukholi α (FNO α) – infliksimab, adalimumab i etanertsept – k aprelyu 2009 g. poluchili bolee 2 mln bol'nykh vo vsem mire. Vse eti preparaty okazalis' odinakovo effektivny (okolo 60% bol'nykh otvetili na lechenie) pri revmatoidnom artrite (RA), ankiloziruyushchem spondilite (AS), psoriaze, psoriaticheskom artrite i odobreny dlya lecheniya etikh boleznei [1, 2]. Odnako ikh ispol'zovanie mozhet byt' svyazano s tselym ryadom neblagopriyatnykh reaktsii, odnoi iz kotorykh yavlyaetsya obostrenie ili razvitie novykh sluchaev psoriaza [3].

Details

ISSN :
19954492 and 19954484
Database :
OpenAIRE
Journal :
Rheumatology Science and Practice
Accession number :
edsair.doi.dedup.....c9e2dc7df11da78b858564b38e1c190c
Full Text :
https://doi.org/10.14412/1995-4484-2011-1466